A broad immunological screening may impact treatment in bronchiectasis patients

Le résumé fourni par la source

The 2017 ERS guidelines suggest a minimum bundle of tests to identify immunodeficiencies (ID) in bronchiectasis (BE), including serum IgG, IgA, IgM, blood count and electrophoresis. To test the hypothesis that an extensive bundle of tests might help in detecting more potentially treatable ID, an observational, prospective study enrolling consecutive non-cystic fibrosis BE adults was conducted at the Bronchiectasis and PCD Program of the Policlinico Hospital in Milan, Italy, from 2016 to 2018. In addition to the minimum bundle, patients underwent serum IgG subclasses, IgE, lymphocytes subsets, HIV test, ANA, ENA, ANCA and anti-CCP screening of tests. Primary ID diagnosis was based on ESID or IDF criteria. Among 450 recruited patients (75% female; median age: 63 years), 149 (33%) had at least one abnormal result at the broad immunological screening and 82 (18.2%) had at least one ID diagnosis (see table). Assessment of IgG subclasses can be helpful to detect potential treatable trait of BE patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.